A detailed history of Kbc Group Nv transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 5,224 shares of ARWR stock, worth $102,965. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,224
Previous 3,580 45.92%
Holding current value
$102,965
Previous $69,000 42.03%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$17.7 - $26.34 $29,098 - $43,302
1,644 Added 45.92%
5,224 $98,000
Q2 2024

Jul 17, 2024

BUY
$21.87 - $28.24 $18,261 - $23,580
835 Added 30.42%
3,580 $93,000
Q1 2024

May 08, 2024

BUY
$27.21 - $39.48 $12,788 - $18,555
470 Added 20.66%
2,745 $79,000
Q4 2023

Feb 13, 2024

BUY
$21.2 - $31.03 $29,044 - $42,511
1,370 Added 151.38%
2,275 $70,000
Q3 2023

Feb 15, 2024

BUY
$26.2 - $36.08 $35,894 - $49,429
1,370 Added 151.38%
2,275 $61,000
Q2 2023

Feb 15, 2024

SELL
$25.16 - $41.38 $34,469 - $56,690
-1,370 Reduced 60.22%
905 $32,000
Q2 2023

Jul 28, 2023

BUY
$25.16 - $41.38 $22,769 - $37,448
905 New
905 $32,000
Q1 2023

Feb 14, 2024

BUY
$23.68 - $38.51 $6,796 - $11,052
287 Added 46.44%
905 $23,000
Q4 2022

Feb 14, 2024

SELL
$28.0 - $40.56 $44,072 - $63,841
-1,574 Reduced 71.81%
618 $25,000
Q2 2022

Jul 26, 2022

SELL
$27.79 - $50.61 $60,915 - $110,937
-2,192 Closed
0 $0
Q1 2022

Feb 14, 2024

SELL
$39.62 - $69.97 $3,288 - $5,807
-83 Reduced 3.65%
2,192 $101,000
Q1 2022

May 06, 2022

BUY
$39.62 - $69.97 $86,847 - $153,374
2,192 New
2,192 $101,000
Q4 2021

Feb 03, 2022

SELL
$58.09 - $82.51 $154,228 - $219,064
-2,655 Closed
0 $0
Q4 2020

Feb 10, 2021

SELL
$43.82 - $85.37 $70,550 - $137,445
-1,610 Reduced 37.75%
2,655 $204,000
Q3 2020

Oct 28, 2020

BUY
$33.21 - $51.27 $134,998 - $208,412
4,065 Added 2032.5%
4,265 $184,000
Q2 2020

Aug 10, 2020

BUY
$26.12 - $43.27 $5,224 - $8,654
200 New
200 $9,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.09B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.